ABCAM PLC: New PBS-Only Antibodies Enable More Flexible Research

Published: Oct 09, 2018

Cambridge, UK – 9 October 2018 – Abcam's new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments.

Typically, antibodies are stored in a buffer composed of bovine serum albumin (BSA), glycerol and sodium azide to ensure stability. However, these components can inhibit effective conjugation to certain dyes and enzymes or they can be toxic to live cells. In a concentrated solution, without BSA, glycerol or azide, PBS-only antibodies are ideally suited to antibody labelling, functional and cell-based assays and live cell imaging applications.

Developed using Abcam’s rabbit monoclonal recombinant technology, the PBS-only antibodies are highly reproducible ensuring batch-to-batch consistency and are extensively validated across a wide range of applications including Flow, WB, ChIP, ICC, IHC and Knockout validation. Abcam is now making over 2300 of these antibodies available, via its catalog for global researchers.

Find out more at: https://www.abcam.com/pbs-only.

- ENDS -

Notes To Editors

About Abcam

As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which in turn will drive new treatments and improved health.

Two-thirds of the world’s 750,000 life science researchers use Abcam’s affinity binders, reagents, biomarkers and assays and the Company’s products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam’s eleven locations are in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 130 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com.

Issued for and on behalf of Abcam plc by Instinctif Partners. 
For more information please contact:

Abcam:
Francesca Axe
T: +44 1223 696000

Media enquiries:
Dr. Lynne Trowbridge
Instinctif Partners
T: +44 (0)20 7457 2861
E: abcam@instinctif.com

Back to news